NanoViricides Inc. (NNVC)

[JG36]

Yup. By the end of the year they will probably have figured out which version of ocular Herpescide to test. Maybe they'll have even started tox testing. That's it. The earliest possible date for clinical trials is mid 2017 and that means there's plenty of time to find reasons for more delay, something NNVC is very good at doing. Meanwhile NNVC will quickly reach the point where it must raise new cash no matter what the stock price.